Emergence of linezolid resistance in hepatobiliary infections caused by Enterococcus faecium

Marc Niebel, M. Thamara P. R. Perera, Tahir Shah, Ravi Marudanayagam, Kate Martin, Beryl A. Oppenheim, Miruna D. David – 3 September 2015 – Enterococcal infections are common in liver transplantation and hepatopancreaticobiliary (HPB) surgery. Linezolid is frequently used to treat not only vancomycin‐resistant Enterococcus (VRE), but also vancomycin‐sensitive Enterococcus (VSE) infections, and resistance can develop.

Keeping high model for end‐stage liver disease score liver transplantation candidates alive

Jacqueline G. O'Leary, Susan L. Orloff, Josh Levitsky, Paul Martin, David P. Foley – 3 September 2015 – As the mean Model for End‐Stage Liver Disease (MELD) score at time of liver transplantation continues to increase, it is crucial to implement preemptive strategies to reduce wait‐list mortality. We review the most common complications that arise in patients with a high MELD score in an effort to highlight strategies that can maximize survival and successful transplantation. Liver Transpl 21:1428‐1437, 2015. © 2015 AASLD.

Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease

Thinesh L. Krishnamoorthy, Joanna Miezynska‐Kurtycz, James Hodson, Bridget K. Gunson, James Neuberger, Piotr Milkiewicz, Ye H. Oo – 3 September 2015 – Patients transplanted for autoimmune hepatitis (AIH) are at risk of recurrent disease. Our current practice is to maintain long‐term low‐dose corticosteroids with additional immunosuppressive agents. This study describes the implications on patients' outcomes, sepsis, and osteoporosis. We collected data on patients transplanted between January 1999 and October 2014 in a single center who survived for more than 6 months.

Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis

Apurva A. Modi, Hector Nazario, James F. Trotter, Manjushree Gautam, Jeffrey Weinstein, Parvez Mantry, Maisha Barnes, Adil Habib, Jean McAfee, Olga Teachenor, Lauren Tujague, Stevan Gonzalez – 3 September 2015 – Combination antiviral therapy involving sofosbuvir (SOF) and simeprevir (SIM) is a treatment option in patients with genotype 1 chronic hepatitis C; however, the safety of this regimen in patients with decompensated cirrhosis is not established.

The dual and opposite role of the TM6SF2‐rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta‐analysis

Carlos J. Pirola, Silvia Sookoian – 1 September 2015 – The aim of this work was to estimate the strength of the effect of the TM6SF2 E167K (rs58542926 C/T) variant on blood lipid traits and nonalcoholic fatty liver disease (NAFLD) across different populations. We performed a systematic review by a meta‐analysis; literature searches identified 10 studies. The rs58542926 exerts a significant role in modulating lipid traits, including total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), triglycerides (TG), and NAFLD.

Longterm health‐related quality of life after living liver donation

Vanessa R. Humphreville, David M. Radosevich, Abhinav Humar, William D. Payne, Raja Kandaswamy, John R. Lake, Arthur J. Matas, Timothy L. Pruett, Srinath Chinnakotla – 31 August 2015 – There are little data on longterm outcomes, health‐related quality of life (HRQoL), and issues related to living donor right hepatectomy specifically. We studied longterm HRQoL in 127 living liver donors.

Subscribe to